Susquehanna International Group
DSGN icon

Susquehanna International Group’s Design Therapeutics DSGN Stock Holding History

Susquehanna International Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,000
Closed -$43.8K – 12680
2025
Q2 		$43.8K Buy
+13,000
New +$48.6K ﹤0.01% 12149
2024
Q1 		– Sell
-91,400
Closed -$242K – 12409
2023
Q4 		$242K Sell
91,400
-8,700
-9% -$19.9K ﹤0.01% 10290
2023
Q3 		$236K Buy
+100,100
New +$467K ﹤0.01% 9858
2023
Q1 		– Sell
-183,900
Closed -$1.89M – 12728
2022
Q4 		$1.89M Buy
183,900
+24,300
+15% +$329K ﹤0.01% 4812
2022
Q3 		$2.67M Buy
159,600
+100,500
+170% +$2M ﹤0.01% 4319
2022
Q2 		$827K Buy
+59,100
New +$798K ﹤0.01% 6998

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's DSGN Position: Q1 2026 in Review

Susquehanna International Group sold out of Design Therapeutics (DSGN) in Q1 2026, closing a stake of 61,852 shares — an estimated $580K sold.

Susquehanna International Group first reported a position in DSGN in Q2 2022 and held it in 14 quarters. The position peaked at $1.75M in Q1 2023. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Susquehanna International Group reported no remaining Design Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 61,852 Design Therapeutics shares in Q1 2026, an estimated $580K.
  • Susquehanna International Group first reported a position in Design Therapeutics in Q2 2022 and held it in 14 quarters.
  • Susquehanna International Group's Design Therapeutics position peaked at $1.75M in Q1 2023.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.